|
PSA
4.1– 6.0 ng/ml
|
|
Gleason Score
|
Pathology Risk
|
Clinical
Stage
|
|
T1c
|
T2a
|
T2b
|
T2c
|
|
2-4
|
Confined
to Prostate
|
90
|
78-98
|
81
|
63-95
|
75
|
55-93
|
73
|
52-93
|
|
Spread to Prostate Capsule
|
10
|
2-22
|
19
|
5-37
|
25
|
7-45
|
27
|
7-48
|
|
Spread to Seminal Vesicles
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
5-6
|
Confined
to Prostate
|
80
|
78-83
|
66
|
62-70
|
57
|
52-63
|
55
|
44-64
|
| |
Spread to Prostate Capsule
|
19
|
16-21
|
32
|
28-36
|
39
|
33-44
|
40
|
32-50
|
| |
Spread to Seminal Vesicles
|
1
|
0-1
|
1
|
1-2
|
2
|
1-3
|
2
|
1-4
|
| |
Spread to Lymph Nodes
|
0
|
0-1
|
1
|
0-2
|
2
|
1-3
|
3
|
1-7
|
|
3+4=7
|
Confined
to Prostate
|
63
|
58-68
|
44
|
39-50
|
35
|
29-40
|
31
|
23-41
|
|
Spread to Prostate Capsule
|
32
|
27-36
|
46
|
40-52
|
51
|
44-57
|
50
|
40-60
|
|
Spread to Seminal Vesicles
|
3
|
2-5
|
5
|
3-8
|
7
|
4-11
|
6
|
2-11
|
|
Spread to Lymph Nodes
|
2
|
1-3
|
4
|
2-7
|
7
|
4-13
|
12
|
5-23
|
|
4+3=7
|
Confined
to Prostate
|
52
|
43-60
|
33
|
254-41
|
25
|
18-32
|
21
|
14-31
|
| |
Spread to Prostate Capsule
|
42
|
35-50
|
56
|
48-64
|
60
|
50-68
|
57
|
43-68
|
| |
Spread to Seminal Vesicles
|
3
|
1-6
|
5
|
2-8
|
5
|
3-9
|
4
|
1-10
|
| |
Spread to Lymph Nodes
|
3
|
1-5
|
6
|
3-11
|
10
|
5-18
|
16
|
6-32
|
|
8-10
|
Confined
to Prostate
|
46
|
36-56
|
28
|
20-37
|
21
|
14-29
|
18
|
11-28
|
|
Spread to Prostate Capsule
|
45
|
36-54
|
58
|
49-66
|
59
|
49-69
|
57
|
43-70
|
|
Spread to Seminal Vesicles
|
5
|
3-9
|
8
|
4-13
|
9
|
4-16
|
7
|
2-15
|
|
Spread to Lymph Nodes
|
3
|
1-6
|
6
|
2-12
|
10
|
4-20
|
16
|
6-33
|
